🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Palisade Bio, Inc. (PALI)
NASDAQ: PALI · Real-Time Price · USD
0.8399
-0.0855 (-9.24%)
At close: Nov 20, 2026, 4:00 PM EST
0.8700
+0.0301 (3.58%)
After-hours: Nov 20, 2026, 7:51 PM EST

Company Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.

Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease.

The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Palisade Bio, Inc.
Palisade Bio logo
CountryUnited States
Founded1996
IndustryBiotechnology
SectorHealthcare
Employees14
CEOJ. Finley

Contact Details

Address:
4600 South Syracuse Street, Suite 900
Denver, Colorado 80237
United States
Phone858 704 4900
Websitepalisadebio.com

Stock Details

Ticker SymbolPALI
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code1357459
CUSIP Number696389402
ISIN NumberUS6963894026
Employer ID52-2007292
SIC Code2836

Key Executives

NamePosition
J. D. FinleyChief Executive Officer, Chief Financial Officer and Director
Dr. Mitchell Lawrence Jones M.D., Ph.D.President and Chief Medical Officer
Ramesh C. Donthamsetty C.F.A.Head of IR and Corporate Strategy
Julien E. CapersGeneral Counsel and Corporate Secretary
Dr. Joerg Heyer Ph.D.Head of Translational Science and Medicine
Dr. James Izanec M.D.Head of Clinical Development
Daniel J. LarkinsHead of Global Regulatory Affairs
Adarsh Patel M.B.A., M.S.Head of Chemistry, Manufacturing and Controls
Dawn LouroHead of Clinical Operations
Ryker WillieHead of Finance and Corporate Controller

Latest SEC Filings

DateTypeTitle
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 10, 20268-KCurrent Report
Nov 10, 202610-QQuarterly Report
Nov 9, 2026SCHEDULE 13G/AFiling
Oct 30, 2026SCHEDULE 13GFiling
Aug 14, 2026SCHEDULE 13G/AFiling
Aug 13, 2026SCHEDULE 13G/AFiling
Aug 10, 20268-KCurrent Report
Aug 10, 202610-QQuarterly Report
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides